Product Description
treatment of neuropathic pain in patients with cancer. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00474916)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: DARA BioSciences|Midatech Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Neuropathic Pain|Neuralgia
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
DTCL100 | P2 |
Completed |
Neuropathic Pain|Neuralgia |
2009-03-01 |
|
NCI-2012-03132 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2008-11-01 |
|
NSC650426 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2000-01-01 |